Trials / Completed
CompletedNCT05765201
Phacoemulsification at High IOP and Physiologic IOP: Impact on Anterior and Posterior Segment Physiology
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 27 (actual)
- Sponsor
- Matthew Rauen · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the anterior and posterior structure and functional changes and vascular alterations when performing phacoemulsification at high IOP vs low, more physiological IOP using Centurion® Vision System with Active Sentry® handpiece. These devices are approved by the US Food and Drug Administration (FDA).
Detailed description
To investigate the anterior and posterior physiological changes when performing phacoemulsification at high IOP vs low, more physiologic IOP using Centurion® Vision System with Active Sentry® handpiece Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP ≤ 28mmHg (low IOP) in one eye and with IOP ≥ 60mmHg (high IOP) in the other eye Operating at lower, more physiological IOP using Active Sentry® handpiece during cataract surgery will use less BSS fluid usage. (Lower IOP settings are also expected to result in less subclinical changes).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | High IOP | Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP ≤ 28mmHg (low IOP) in one eye and with IOP ≥ 60mmHg (high IOP) in the other eye |
| OTHER | Low IOP | Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP ≤ 28mmHg (low IOP) in one eye and with IOP ≥ 60mmHg (high IOP) in the other eye |
Timeline
- Start date
- 2022-09-22
- Primary completion
- 2023-05-04
- Completion
- 2023-05-04
- First posted
- 2023-03-13
- Last updated
- 2024-01-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05765201. Inclusion in this directory is not an endorsement.